Capstone Investment Advisors LLC Reduces Stake in BioNTech SE (NASDAQ:BNTX)

Capstone Investment Advisors LLC lowered its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 57.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,767 shares of the company's stock after selling 3,774 shares during the period. Capstone Investment Advisors LLC's holdings in BioNTech were worth $315,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its stake in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. lifted its holdings in shares of BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE purchased a new stake in shares of BioNTech during the fourth quarter valued at $90,000. GAMMA Investing LLC increased its holdings in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after buying an additional 300 shares in the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new position in BioNTech in the 4th quarter worth about $137,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Price Performance

Shares of BNTX stock traded down $2.01 during mid-day trading on Friday, hitting $92.77. The company had a trading volume of 607,283 shares, compared to its average volume of 921,180. The company has a market capitalization of $22.26 billion, a P/E ratio of -44.18 and a beta of 1.35. The stock's 50 day moving average price is $98.79 and its 200-day moving average price is $109.51. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the business posted $1.90 earnings per share. The business's quarterly revenue was down 19.5% compared to the same quarter last year. Equities research analysts forecast that BioNTech SE will post -3.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BNTX. Citigroup reiterated a "buy" rating and issued a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday. BMO Capital Markets boosted their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Morgan Stanley cut their price objective on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday. Canaccord Genuity Group restated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Truist Financial started coverage on shares of BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $142.73.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.